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Stroke is a leading cause of death and long-term disability worldwide. Current
therapeutic options are limited in terms of their time for implementation and efficacy
in promoting recovery. Cell transplantation has been shown to have promise in several
animal models however significant challenges remain, including the optimal source of
cells to promote neural repair. Here, we report on the use of a population of human
ESC derived, cortically specified, neuroepithelial precursor cells (cNEPs) that are neurally
restricted in their lineage potential. CNEPs have the potential to give rise to mature neural
cell types following transplantation, including neurons, astrocytes and oligodendrocytes.
With a view towards translation, we sought to determine whether this human cell
source was effective in promoting improved functional outcomes following stroke.
Undifferentiated cNEPs were transplanted in a pre-clinical endothelin-1 (ET-1) model of
ischemic motor cortical stroke in immunocompromised SCID-beige mice and cellular
and functional outcomes were assessed. We demonstrate that cNEP transplantation in
the acute phase (4 days post-stroke) improves motor function as early as 20 days post-
stroke, compared to stroke-injured, non-transplanted mice. At the time of recovery, a
small fraction (<6%) of the transplanted cNEPs are observed within the stroke injury
site. The surviving cells expressed the immature neuronal marker, doublecortin, with
no differentiation into mature neural phenotypes. At longer survival times (40 days), the
majority of recovered, transplanted mice had a complete absence of surviving cNEPS.
Hence, human cNEPs grafted at early times post-stroke support the observed functional
recovery following ET-1 stroke but their persistence is not required, thereby supporting a
by-stander effect rather than cell replacement.
Keywords: stroke, mouse behavior, human stem cell transplantation, stem cell survival and differentiation, human
neuroepithelial cell, immunogenic response
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INTRODUCTION
Stroke is a leading cause of death and disability in adults
(Khoshnam et al., 2017). Current treatment options are limited
and do not promote complete recovery after stroke, leaving
patients with poor quality of life and socioeconomic hardship.
One potential treatment to improve outcome following stroke
involves transplantation of stem and progenitor cells (termed
precursor cells). This approach has been shown to be effective
in animal models of stroke (Mohamad et al., 2013; Xiong
et al., 2017; Payne et al., 2018; Vonderwalde et al., 2019),
however, several hurdles remain, including the identification
of an optimal cell source to promote neural repair and
functional recovery.
A variety of cell sources have been explored in transplant
studies to treat stroke. Embryonic stem cells (ESCs) and induced
pluripotent stem cells (iPSCs) can give rise to all cell types
in the central nervous system (CNS), however they have
reported tumorigenic capacity upon transplantation, limiting
their efficacy (Thomson et al., 1998; Gao et al., 2016a). A recent
approach to reducing the tumorigenic potential of transplanted
cells involves the use of genome-editing strategies to insert
a suicide gene into a cell division essential locus, allowing
selective ablation of proliferating cells through administration
of a pro-drug (Payne et al., 2019a). Other approaches
to circumvent tumorigenicity include the transplantation of
neurally committed cells with less tumorigenic potential (Gao
et al., 2016b). For stroke application, previous studies have shown
efficacy of both mesenchymal stem cells and neural precursors in
improving motor recovery by enhancing host neuroplasticity as
measured by increased synapse formation, without the need for
integration and maturation (Wakabayashi et al., 2009; Oki et al.,
2012; Vonderwalde et al., 2019). Additionally, studies suggest
that neural stem cells mediate recovery through maturation and
integration of transplanted cells (Zhou et al., 2015; Ficek et al.,
2016). Herein, we have examined the potential of human ESC
derived, cortical neuroepithelial cells (cNEPs). These neurally
committed cells are present during brain development and have
the capacity to generate cortical neural cell types in vitro. Hence,
cNEPs provide regionally specific brain cells for transplantation
in a cortical stroke injury model (Tornero et al., 2017; Payne
et al., 2019b) and the opportunity to evaluate whether cNEPs
promote improved functional outcomes by examining grafted
cell survival, maturation and integration.
CNEPs are found in the developing neural tube, where
they generate radial glia progenitors, neurons, astrocytes and
oligodendrocytes (Martínez-Cerdeño andNoctor, 2018). In vitro,
cNEPS can be derived from pluripotent stem cells, including
iPSCs and ESCs (Guillaume et al., 2006; Payne et al., 2018).
A previous study used iPSC derived cNEPS in a rat model
of motor stroke that lesioned the cortex and striatum, and
demonstrated minimal improvements in functional outcomes
when transplanted in a hydrogel (Payne et al., 2019b). Whether
ESC derived cNEPs can improve stroke outcomes in a mouse
model of motor cortex stroke, has not been explored. Further,
with a view towards translation and in accordance with stroke
therapy academic industry roundtable (STAIRS) and the stem
cell therapies as an emerging paradigm in stroke (STEPS)
guidelines, it is important to demonstrate the efficacy of cNEPs
in more than one model of stroke to advance therapeutics
(Lapchak et al., 2013).
Here, we use an endothelin-1 (ET-1) model of focal ischemic
stroke in the motor cortex that mimics the human condition.
ET-1 is a potent vasoconstrictor that results in the formation
of a lesion cavity, surrounding penumbra and formation of a
glial scar—hallmarks of the cellular response to ischemic insult
(Adkins et al., 2004; Horie et al., 2008; Erlandsson et al., 2011;
Sachewsky et al., 2014). The model is reproducible and generates
measurable functional impairments that permit the evaluation
of the efficacy of transplanted cells in promoting neural repair.
CNEPs were transplanted on post-stroke day 4 (PSD4; acute
phase) and we observed a rapid and significantmotor recovery by
PSD20. Interestingly, at the time of recovery, the vast majority of
cNEPS were no longer present in the injured tissue and surviving
transplanted cells had immature neural phenotypes. Groups of
mice that survived to PSD40 continued to display functional
recovery in the absence of cell maturation and further, 67% of the
recovered mice were devoid of surviving transplanted cells. Our
study demonstrates that integration and maturation of cNEPs




Human H1 ESC (WiCell, Madison, WI, USA) were grown
on Geltrex-coated (Thermo Fisher Scientific, Waltham,
MA, USA) culture plates in mTESR1 medium (StemCell
Technologies, Vancouver, BC, Canada) containing 1% PenStrep
(Sigma–Aldrich, St. Louis, MO, USA). Cells were lifted with
TrypLE (Thermo Fisher Scientific, Waltham, MA, USA)
and passaged at 1.5 × 104 cells per cm2, into induction and
maintenance media containing a cocktail of small molecule
inhibitors to generate cNEPs, as previously described (Payne
et al., 2018; Varga et al., 2021). Briefly, H1 ESC were induced
into cNEPs using media containing 50% DMEM-F12, 50%
Neurobasal (Thermo Fisher Scientific), 0.5× N2 supplement
(Gibco), 0.5× B27 supplement (Gibco), 1 mM Glutamax
(Thermo Fisher Scientific), 25 mM 2-mercaptoethanol (Sigma).
H1 ESC were passaged in media supplemented with 10 µM
SB431542 and 100 nM LDN193189 and 10 µM Y27632. Media
was changed every other day and kept for 8 days prior to
passaging into maintenance media.
CNEP In vitro Culture and Differentiation
CNEPs were cultured on laminin-coated culture plates, lifted
with TrypLE (Thermo Fisher Scientific, Waltham MA, USA)
and passaged at 3 × 104 cells/cm2 for 4–10 passages prior
to transplantation. For transplant, cNEPs were pelleted and
resuspended in regular artificial cerebrospinal fluid (aCSF) at
1 × 105 cells/µl and kept on ice for up to 2 h before intracranial
injection. Media contained 50% DMEM-F12, 50% Neurobasal,
25mM2-mercaptoethanol, 1 mMGlutamax, 1×N2 supplement,
0.05× B27 minus vitamin A supplement (Gibco), further
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supplemented with 2 µM CHIR99021 (Peprotech), 1 µM
XAV939, 1 µM SB431542 (Peprotech), 10 ng/ml FGF2
(PeproTech), 50 nM LDN193189, 50 nM K02288, 50 nM
AKTiVIII (Calbiochem) and 75 nM MK2206 (all other material
from Selleck Chem). For transplant, cNEPs were pelleted and
resuspended in regular artificial cerebrospinal fluid (aCSF) at
1 × 105 cells/µl and kept on ice for up to 2 h before intracranial
injection.
For in vitro characterization, cNEPs were cultured in
differentiation media containing 50% DMEM/F12 (Thermo
Fisher Scientific, Waltham, MA, USA), 50% Neurobasal
(Thermo Fisher Scientific, Waltham, MA, USA), 0.2× Insulin
with Zinc (Thermo Fisher Scientific, Waltham, MA, USA),
0.2× N2 supplement (National Library of Medicine (2017),
0.1× B27 with Vitamin A (Thermo Fisher Scientific, Waltham,
MA, USA), 25 mM 2-Mercaptoethanol (Sigma–Aldrich, St.
Louis, MO, USA), 1 mM Glutamax (Thermo Fisher Scientific,
Waltham, MA, USA) and 0.075× FBS (Wisent, Saint-Jean-
Baptiste, QC, Canada). Media was changed every other day for
up to 14 days. Cells were cultured in maintenance medium and
fixed 48 h after plating (undifferentiated cells) or 14 days after
plating (differentiated cells) with 4% paraformaldehyde, followed
by immunocytochemistry. Cells were blocked with 5% normal
goal serum (Sigma–Aldrich, St. Louis, MO, USA) in PBS and
0.5% TritonX-100 (Sigma–Aldrich, St. Louis, MO, USA) for
1 h at room temperature. Cells were incubated with primary
antibodies diluted in blocking solution, overnight at 4◦C.
Immunocytochemistry was performed using DAPI (Invitrogen,
Carlsbad, CA, USA), anti-OCT4 (1:200; BD Biosciences, 611202),
anti-human Nestin (1:50; Millipore, Sigma, ABD69), anti-SOX2
(1:1,000; Abcam, AB97959), anti-BIII tubulin (1:1,000; Sigma,
T8860), anti-DCX (1:250; AB18723), anti-Olig2 (1:200; AB9610)
and anti-GFAP (1:1,000; Dako, Z0334). Secondary antibodies,
Alexa Fluor488 (Invitrogen, Carlsbad, CA, USA) and Alexa
Fluor568 (Invitrogen, Carlsbad, CA, USA) were diluted in 5%
NGS. Cell markers colocalized with DAPI were counted from
three images per well for differentiated cNEP cell counts.
Animals
Male Fox Chase SCID/Beige (Jackson Labs, Bar Harbor, ME,
USA)mice, aged 10–15 weeks were used for all studies.Mice were
housed with ad libitum food and water. Following stroke surgery,
mice were housed individually. All experiments were conducted
in accordance with the University of Toronto, Temerty Faculty of
Medicine Animal Care Committee and with Canadian Council
on Animal Care guidelines.
ET-1 Stroke
ET-1 stroke was performed as previously described
(Vonderwalde et al., 2019). Briefly, the skull was exposed, a
small burr hole was drilled at the site of the right sensorimotor
cortex at AP:+ 0.6 mm,ML:−2.2 mm lateral to bregma and DV:
−1.0 mm. Mice received a 1 µl injection of 800 picomolar ET-1
in distilled H2O (Millipore, Sigma, St. Louis, MO, USA) using
a 2.5 µl Hamilton Syringe with a 26 gauge, 0.375′′ long needle
(Hamilton, Reno, NV, USA). ET-1 was injected at a rate of 0.1
µl/min. The needle was removed 10 min after the last injection.
Mice were given saline, 5 mg/kg meloxicam as analgesic and
allowed to recover. Mice were divided into two groups, Stroke
alone and Stroke+ cNEP transplant.
CNEP Transplant
On PSD4, mice in the Stroke + cNEP group received cNEP
transplants. CNEPs were lifted with TrypLE (Thermo Fisher
Scientific, Waltham, MA, USA) and added 1:1 with DMEM
containing 10% FBS (Wisent, Saint-Jean-Baptiste, QC, Canada),
counted, pelleted, and resuspended in aCSF at a concentration
of 1 × 105 cells/µl, as previously described (Payne et al., 2019b).
Cells were injected through the previously drilled burr hole at
the same coordinates as the ET-1. One-hundred thousand cells
in 1 µl of a CSF was injected using a Hamilton syringe. Control
mice received 1 µl of a CSF.
Tissue Processing and Analysis
On PSD4, PSD8, PSD20 and PSD40, mice were deeply
anaesthetized with 250 mg/kg Avertin (Sigma–Aldrich, St.
Louis, MO, USA) and intracardially perfused with phosphate
buffered saline (PBS) (10 ml/min for 3 min), followed by
4% paraformaldehyde at a rate of 6 ml/min for 5 min.
Brains were removed and post-fixed at 4◦C overnight in 4%
paraformaldehyde and then stored in 30% sucrose until use.
Brains were cryosectioned (−20◦C) at 20 µm sections, placed
on SuperFrost slides (Thermo Fisher Scientific, Waltham, MA,
USA) and stored at−20◦C.
At the time of processing, sections were washed with PBS
and blocked using 1% bovine serum albumin (Sigma–Aldrich,
St. Louis, MO, USA), 4% normal goal serum (Sigma–Aldrich,
St. Louis, MO, USA) and 0.5% TritonX-100 (Sigma–Aldrich, St.
Louis, MO, USA) in PBS for 1 h at room temperature. Sections
were incubated with primary antibodies: anti-human Nestin
(1:50; Millipore, Sigma, ABD69), anti-HuNu (1:200; Millipore,
Sigma, MAB1281), anti-SOX2 (1:1,000; Abcam, AB97959),
anti-DCX (1:250; AB18723), anti-NeuN (1:100; Millipore, Sigma,
ABN78), anti-GFAP (1:400, Sigma, G3893), anti-MBP (1:50;
Abcam, AB7349), anti-Ki67 (1:200, AB15580) and anti-Iba1
(1:500, Wako 019–19741) in blocking solution overnight at
4◦C. After 3 × 5 min PBS washes, tissue was incubated
with secondary antibodies, Alexafluor488 and 568 (1:1,000;
Invitrogen) at room temperature for 1 h. Another 3× PBS washes
were performed and sections were mounted using Vectashield
with DAPI (Vector, H-1,200). Images were acquired on an
inverted Zeiss LSM880 laser scanning confocal and on an
Axio Observer Zeiss microscope at 10× and 20× magnification
for counting. Colocalized antibody staining with DAPI was
counted manually. All brain sections through the stroke injury
site were assessed and all sections (range 1–10 sections/brain)
that contained transplanted cells were quantified. Cell counts
were performed on sections from both treatment groups
surrounding the stroke lesion and from sections containing
HuNu+ cells from transplanted mice. Three 400 µm × 400
µm areas surrounding the stroke lesion (lateral, medial and
inferior) were counted. For Iba1+ cells, the total numbers, as
well as those ameboid in shape (with one or less processes),
were counted in the same three areas surrounding the lesion
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and in a minimum of three sections per brain from both
treatment groups.
Histology
The sections were hydrated for 5 min each in 100% ethanol,
95% ethanol and 70% ethanol. Then, rinsed in distilled
H2O for 1 min and stained using 0.25% cresyl violet in
0.0025% glacial acetic acid and distilled H2O for 15 min.
Wash steps involved 2 min each of submersion in distilled
H2O and 95% ethanol. The sections were then placed in 0.25%
glacial acetic acid in 95% ethanol for 1 min, dehydrated for
20 s in 100% ethanol, cleared using xylene and mounted
using DPX mounting medium (Sigma–Aldrich, St. Louis,
MO, USA). Images were taken at 5× magnification on an
Axio Observer Zeiss microscope. AxioVision software and
ImageJ were used to trace the stroke lesion as previously
described (Vonderwalde et al., 2019) and volume was
calculated using the average lesion area × the number of
sections with lesions × the distance between the sections
(160 µm).
Foot-Fault
The foot fault test was performed to assess motor function and
coordination. Mice were placed on a metal grid (1 cm spaces)
suspended 12 inches above a table surface and video recorded
while mice traversed the grid for 3 min. Uninjured animals
demonstrate good coordination and slip minimally during this
task. The number of steps and the number of foot slips made
with the forelimbs were counted and the difference in foot slip
ratio was calculated as (number of contralateral paw slips −
number of ipsilateral paw slips)/total number of steps × 100.
Mice that did not exhibit a behavioral deficit in foot-fault greater
than 1 standard deviation from their mean baseline values were
removed from further analysis.
Catwalk
Catwalk was performed by placing mice at the entrance of a
narrow glass walkway with a dark goal box on the opposite end
of the walkway. As mice walked across the glass walkway to the
goal box, paw prints as beam breaks were recorded on a video
camera placed below the walkway. CatwalkXT software v10.6
(Noldus) was used to analyze print data and obtain quantitative
parameters for gait analysis (Kappos et al., 2017). Terminal
dual stance measured the duration of simultaneous contact of
contralateral paws. Support Lateral measured the percent of the
walk where simultaneous contact was made with lateral hindlimb
and forelimb.
Statistical Analysis
Statistical analysis was conducted using V6 GraphPAD Prism
and IBM SPSS v23. Foot fault and Catwalk were analyzed by
repeated measures ANOVA, Tukey’s post hoc test and across
group comparisons at individual timepoints were analyzed
with Student’s T-test, Mann–Whitney post hoc. All data
was represented as mean ± SEM. Significant differences are
considered p < 0.05.
RESULTS
CNEPs Are Multipotent, Neurally
Committed Cells In vitro
ES cells were plated and expanded in ES conditions prior
to inducing and plating in cNEP conditions. To examine
the neural differentiation potential of the cNEPs plated,
cNEPs were collected and replated in maintenance media
for 2 days (undifferentiated) or differentiation media for
14 days (differentiated) and immunocytochemistry was
performed. Undifferentiated cNEPs expressed the NPC markers
Sox2 and Nestin and did not express the pluripotency marker
Oct4 expressed by ESCs (Figure 1A). Following 14 days of
differentiation, the majority of cNEPs differentiated into
DCX + neuroblasts (44.6 ± 5.2%) and BIII-tubulin + immature
neurons (30.3 ± 5.5%), with fewer cNEPs expressing the
astrocytic marker GFAP (15.9 ± 10.2%) and oligodendryocyte
marker Olig2 (6.8 ± 1.7%; Figures 1B,C; Mujtaba et al., 1999;
Payne et al., 2019b). Hence, similar to human iPSC derived
cNEPs (Payne et al., 2019b), ESC derived cNEPs are multipotent,
neurally committed cells in vitro.
Transplanted cNEPs Improve Motor
Function Following Stroke
CNEPs were transplanted into the stroke lesion of
immunocompromised SCID-Beige mice on PSD4 (acute
phase) following an ET-1 induced stroke in the motor cortex
(Vonderwalde et al., 2019). All mice were tested in the foot-fault
task prior to stroke to establish baseline behavior, and again
on PSD3 prior to cell transplantation (Figures 2A,B). Stroke
injured mice displayed motor deficits in foot-fault at PSD3,
relative to baseline performance (Figure 2B). On PSD4, one
cohort of mice (Stroke + cNEP) received 1 × 105 cNEP cells
into the stroke injury site. Stroke only mice received vehicle
injections. Motor behavior was assessed in the Stroke + vehicle
and Stroke + cNEP groups on PSD8, PSD20 and PSD40
(4, 16 and 36 days post-transplant). As shown in Figure 2B,
mice that received cNEPs displayed significantly improved
motor outcomes on PSD20 compared to non-transplanted mice
and their motor performance was not significantly different
from baseline (pre-stroke) values on PSD8 or PSD20. Mice that
received cNEP transplant also had improved motor function
compared to stroke untreated mice on PSD20 (Figure 2B).
Mice that did not receive cNEP transplants continued to show
significant motor deficits compared to their baseline on PSD20
(Figure 2B). Notably, the non-transplanted mice underwent
spontaneous recovery by PSD40 and their motor function
was not significantly different from the Stroke + cNEP group
(p = 0.93). Hence, cNEP transplantation improved motor
function following ET-1 induced motor cortical stroke as early
as PSD20.
To assess motor coordination, we used the Catwalk for
gait analysis on PSD20. A number of parameters have been
shown to be affected following stroke, including terminal dual
stance which measure the time that both hindlimbs remain on
the platform (Liu et al., 2013; Caballero-Garrido et al., 2017).
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FIGURE 1 | Embryonic stem cell (ESC) derived cortical neuroepithelial cells
(cNEPs) are neurally committed, multi-potent cells. (A) ESC were induced into
cNEPs and then passaged or differentiated in media prior to
immunocytochemistry. ESC derived cNEPs do not express the pluripotency
marker OCT4 (i) and do express the undifferentiated neural precursor markers
Sox2 (ii) and human Nestin (hNestin) (iii). (B) cNEPs were plated on day 0 in
differentiation media for 14 days. Subpopulations of cells express BIII-tubulin
(i), DCX (ii), Olig2 (iii) and GFAP (iv). Scale bars = 50 µm. (C) Quantification
of differentiation markers. n > 3 independent experiments/condition.
Similar to previous reports using MCAO stroke, ET-1 stroked
mice demonstrated a significant increase in left hindlimb
stance on PSD20, that was reduced in mice that received
cNEP transplantation (Figure 2C). Support lateral measures the
percent of time during the walk that mice are simultaneously
using ipsilateral paws (lateral forelimb and hindlimb). Again,
similar to what is observed in MCAO stroked mice, ET-1
stroked mice demonstrated a decrease in the percent of the
run that hindlimbs and forelimbs simultaneous make contact
during locomotion. This parameter also improved with cNEP
transplant on PSD20 (Figure 2C). These findings demonstrate
that post-stroke impairments in motor coordination as measured
by gait analysis are improved following cNEP transplantation.
Immature cNEPs rescue motor deficit following a stroke.
Given the improved functional outcomes in transplanted
mice, we next examined the cellular response in Stroke + cNEP
treated mice. We assessed the differentiation profile of the
surviving transplanted cells at the time of functional recovery by
looking for co-labeled cells expressing human antigen markers,
HuNu+ or hNestin+, with markers for mature neurons (NeuN),
astrocytes (GFAP) and oligodendrocytes (myelin basic protein
(MBP). As shown in Figure 3A, on PSD20, the vast majority
of HuNu+ cNEPs expressed the neuroblast marker DCX
(92 ± 11%; Figures 3Ai–C), with rare cells expressing the
mature neuronal marker NeuN (2.6 ± 4.5%; Figures 3Aii–C).
Virtually no HuNu+ cells expressed the astrocyte marker GFAP
(Figures 3Aiii–C). We used Ki67 to look for proliferating
cells and observed a small number of Ki67+/HuNu+ cNEPs
(13 ± 13%) on PSD20 (Figure 3Aiv). As predicted, the
contralateral hemisphere of Stroke + cNEP and Stroke only
brains did not contain HuNU+ or Ki67+ cells (Supplementary
Figure 1). Hence, on PSD20, surviving cNEP derived cells were
DCX+, immature neurons.
Since transplanted human cells take longer to differentiate
into mature phenotypes, we predicted that mature neurons may
develop with longer survival times. We examined the brains of
Stroke + cNEP mice on PSD40. Even at this longer survival
time, transplanted cells continued to express DCX with rare
HuNu+ or hNestin+ cells expressing the mature cell markers
NeuN, GFAP or MBP (Figures 3Bi–iii). The contralateral
hemisphere of Stroke + cNEP and Stroke only brains did
not contain transplanted or proliferating cells (Supplementary
Figure 2).
The number of surviving transplanted cells was quantified
on PSD8 (a time when functional deficits were observed),
PSD20 and PSD40 (when functional recovery is observed). The
percentage of surviving cells (HuNu+ and DAPI+) relative to
the numbers of transplanted cells (100,000 cells/brain) was not
significantly different at any time examined (Figure 3D). Most
striking, only three of the nine mice examined on PSD40 had
surviving cNEPs (HuNu+ or hNestin+ cells). Hence, while
Stroke + cNEP mice displayed improved motor function after
PSD20, the recovery was not coincident with surviving cells
on PSD40.
CNEP Transplantation Does Not Affect
Stroke Lesion Volume or the
Microglia/Macrophage Response
We next asked if the lesion volume was affected by the
transplantation and associated with functional improvement.
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FIGURE 2 | cNEP transplantation improves motor outcomes of stroke by PSD20. (A) Schematic of experimental paradigm. FF, foot-fault and
IHC, immunohistochemistry. (B) The percent slippage ratio was scored in Stroke + vehicle and Stroke + cNEP treated mice. Both groups display a motor deficit on
PSD3 and PSD8 compared to baseline performance. Stroke + cNEP mice recover by PSD8 and PSD20 when compared to baseline and is significantly improved
compared to Stroke + vehicle mice (Student’s T-test, Mann–Whitney post hoc). Stroke + vehicle mice maintain the stroke motor deficit on PSD8 and PSD20,
compared to baseline. Stroke + cNEP (n = 10 mice); Stroke + vehicle (n = 10 mice) Two-way ANOVA, Tukey’s post hoc. (C) Catwalk was used to measure gait
parameters after stroke with or without cNEP transplantation. Terminal dual stance measures the duration (ms) of simultaneous contact of both hindpaws. The
duration of the left hindlimb terminal dual stance was significantly increased in Stroke + vehicle mice compared to Stroke + cNEP mice. Support lateral is a
measurement of the time when ipsilateral paws (lateral forelimb and hindlimb) make simultaneous contact during the walking task Stroke + vehicle mice exhibited
significantly impaired support lateral gait pattern compared to Stroke + cNEP treated mice (n=6 mice/group). All statistics were performed with Two-way ANOVA,
Tukey’s post hoc. Data shown as mean ± SEM. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001.
Cresyl violet stained images were quantified from cNEP
transplanted mice sacrificed on PSD4 (prior to transplant) and
PSD40. Cortical lesion volumes were not different between
PSD4 and PSD40 in Stroke + cNEP transplanted mice
(Figure 4A). Hence, cell transplantation does not lead to a change
in the lesion volume at a time of functional recovery.
To determine whether cNEP transplantation affected the
immunological response in stroke injured mice, the number of
Iba1+ inflammatory cells (microglial and macrophages) were
counted in the lesional and perilesional stroke injured cortex.
SCID-beige mice lack the adaptive immune response but retain
the innate immune response (Figure 4B). We observed no
difference in the numbers of Iba1+ cells or the number of
activated ameboid Iba1+ cells in Stroke only and Stroke+ cNEP
transplanted mice on PSD8, a time when immune cell activity
is robust in response to stem cell transplantation (Walczak
et al., 2007; Figures 4B,C). Hence, cNEP transplantation
post-stroke does not elicit an enhanced neuroinflammatory
response compared to Stroke alone.
DISCUSSION
Stem cell transplantation is a promising approach to treat
the stroke injured brain. Despite the promise, a number of
challenges still exist including the identification of an appropriate
cell source, the location and timing of transplantation, and
a clear understanding of the mechanisms that underlie the
potential efficacy of the approach (Bliss et al., 2007). Here,
we demonstrate that the acute transplantation of cNEPs in
an ET-1 motor cortex stroke model can promote functional
recovery as early as 16 days post-transplantation. We found
that only a small fraction of the transplanted cells survive
in the stroke injury site at the time of recovery, and despite
their ability to differentiate into mature phenotypes in vitro,
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FIGURE 3 | Transplanted CNEPs express doublecortin, a marker of immature neurons. (A) Coronal schematic of forebrain at PSD20 HuNu+ or
hNestin+ transplanted cNEPs express DCX (i), low levels of NeuN (ii) and are GFAP negative (iii). A small number of cells express Ki67 (iv). Scale bar = 25 µm.
(B) By PSD40, HuNu+ or hNestin+ transplanted cNEPs express DCX (i), but do not colocalize with mature cell markers NeuN (ii), GFAP (iii) or MBP (iv). Scale
bars = 50 µm. (C) Quantification of the differentiation phenotype of HuNu+ cNEP cells in the PSD20 brain showing majority of transplanted cells are
DCX + immature neurons. (n = 3 mice). (D) The total numbers of HuNu+/DAPI+ cells showed no significant difference between the numbers of surviving cells on
PSD8 (n = 3 mice), PSD20 (n = 3 mice) or PSD40 (n = 9 mice). Data represents mean ± SEM. One-way ANOVA, Tukey’s post hoc; ns, not significant. Arrowheads
indicate cells expressing mature or immature neuronal markers.
the surviving cNEPs remained immature in vivo, at the time
of functional recovery. Further, we demonstrate that improved
functional outcomes are not dependent on the persistence of
the transplanted cells once improved functional outcomes have
been achieved.
Cell integration and replacement are recognized as
mechanisms for functional recovery (Englund et al., 2002;
Falkner et al., 2016; Palma-Tortosa et al., 2020). This
mechanism requires long term survival, maturation, and
integration of transplanted cells to form synaptic connectivity
with endogenous cells for functional benefits. Our study
demonstrates that cNEP survival, maturation and integration
are not required for the by-stander effect observed at early
timepoints that give rise to the recovery we observed in this
ET-1 stroke model. This is consistent with previous studies
using human directly reprogrammed neural precursor cells
in the same ET-1 mouse model of stroke (Vonderwalde
et al., 2019). The complete absence of cells on PSD40 in
67% of the recovered mice, in combination with the lack of
mature neurons suggests that cNEPs support recovery through
‘‘by-stander’’ effects such as secreting factors that enhance
host neuroplasticity and cell maturation is not needed to
maintain behavioral recovery (Xiong et al., 2017). The release
of neurotrophic factors could significantly impact the stroke
niche to induce angiogenesis, decrease immunogenic response
and improve endogenous stem cell response (Horie et al.,
2011; Oliveira et al., 2016). Indeed, the well documented ability
of mesenchymal stem cell transplantation to support brain
repair post-stroke is shown to be mediated by enhancing
brain plasticity and/or reducing the inflammatory response
(Kurozumi et al., 2005; Noh et al., 2016; Forsberg et al., 2020;
Venkat et al., 2020). Identifying the factors that allow for
recovery will be beneficial in determining future avenues of
stroke treatment.
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FIGURE 4 | Transplanted cells do not alter the lesion volume or the inflammatory cell response. (A) Cresyl violet cross section of the stroke injured cortex on
post-stroke day 4 (PSD4). Dotted line delineates the stroke lesion. The lesion volume is not significantly different between PSD4 (pre-transplant) and PSD40
(Stroke + cNEPs). n = 3 mice/group; data represents mean ± SEM; Student’s t-test. Scale bar = 500 µm. (B) Iba1+ inflammatory microglia were stained in
Stroke+ vehicle (i) and Stroke + cNEP (ii) treated mice on PSD8. Scale bar = 50 µm. (C) Quantification of iba1+ cells showed no significant difference in the
number of Iba1+ cells or activated Iba1+ cells between groups (n = 3 mice/group). Data represents mean ± SEM; Student’s t-test. Arrowheads indicate
iba1+ amoeboid shaped cells.
The differentiation profile of transplanted cNEPs suggests
that unlike previous transplant studies, cNEPs do not contribute
to the glial scar by turning into GFAP+ astrocytes (Payne et al.,
2019b; Vonderwalde et al., 2019). Astrocytes have been shown
to be beneficial following brain injury by limiting the extent
of damage, releasing neurotrophic factors and clearing excess
glutamate (Barreto et al., 2012; Liu and Chopp, 2016). However,
astrocytes are also capable of releasing proinflammatory factors
and inhibitory factors, such as chondroitin sulfates, that
impair axonal growth (Barreto et al., 2012). Once activated,
astrocytes exist within the brain in either anti-inflammatory
or pro-inflammatory states (Giovannoni and Quintana, 2020)
and reducing pro-inflammatory astrocyte activation has been
shown to be beneficial for both behavioral and cellular outcomes
after injury (Brambilla et al., 2005). Since the nature of
the astrocytes derived from transplanted cells is not known,
it is possible that the lack of CNEPs derived astrogliosis
is advantageous.
Our study found that a small number of cNEPs expressed the
proliferation marker Ki67, which is consistent with the previous
study transplanting cNEPS into stroke injured rats (Payne et al.,
2019b). Despite the positive functional outcomes and the fact that
majority of mice had no surviving cells on PSD40, the presence
of proliferating cells can be a concern for clinical application.
Ablating proliferating cells using gene editing technologies that
result in cell death upon expression of a cell division gene, CDK1,
have been recently described (Liang et al., 2018; Payne et al.,
2019a) and incorporating this Failsafe system into cNEPs would
undoubtedly enhance their clinical application.
CNEP’s can be derived from pluripotent stem cells, including
iPSCs (Payne et al., 2018, 2019b) and ES cells (reported
here). A previous report using iPSC derived cNEPs embedded
in a hydrogel and transplanted in a subacute rat model of
motor stroke, demonstrated limited improvements in functional
recovery at >50 days post-stroke (Payne et al., 2019b). Payne
et al. (2019b) found that most of the cNEPs survive following
transplantation (on PSD50) and the majority differentiated
into astrocytes. Several differences between the studies are
noted, including the cell origin of cNEPs. IPSCs and ESCs
have been shown to generate different progeny in the same
culture conditions (Kim et al., 2010). Additionally, in the
rat study cNEPs were delivered in a hydrogel which would
modify the interaction of cNEPs with the host environment,
potentially impacting the time of recovery and the differentiation
profile of the transplanted cells. Further, the rat stroke model
included cortical and subcortical ET-1 lesions, with the cell
transplantation being limited to the cortex. Given that cNEPs
are cortically specified, the limited recovery observed in their
study may be related to the fact that striatal circuitry was
disrupted and not impacted by the cNEP transplant. Together,
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the outcomes of the in vivo studies comparing cells that behave
similarly in vitro, highlight the importance of following the
recommendations of STEPS and STAIRS that underscore the
need to compare outcomes across different models, with a view
towards translation (Lapchak et al., 2013).
When considering stem cell transplantation studies to
treat stroke, there are a number of design parameters that
can influence outcomes and make it challenging to compare
across studies. For example; the cell source, the numbers of
cells transplanted, the location and time of transplantation
post-stroke and the vehicle used to transplant cells. Our
study paradigm was based on the findings that stem cell
transplantation into the stroke lesion provided greater survival
and functional improvement following stroke, when compared
to transplantation into surrounding parenchyma following ET-1
stroke (Ballios et al., 2015). In addition, we have found that the
use of a hydrogel (HAMC) did not provide improved survival
of human neural stem cells when transplanted into SCID-beige
immunodeficient mice (Vonderwalde et al., 2019). Building on
these studies we transplanted human cNEPs into the stroke
lesion site suspended in regular cerebrospinal fluid in SCID-beige
immunocompromised mice. Importantly, this method allowed
us to avoid pharmacological immunosuppression, as these
treatments have been shown to regulate endogenous neural
precursor behavior which could influence the outcomes
(Sachewsky et al., 2014). These experimental considerations
are important for ensuring best approaches in pre-clinical
stroke research.
Our study demonstrates that cortically specified, neurally
committed neural precursor cells can promote rapid functional
recovery when delivered in the acute phase post stroke
without integration into the host circuitry. Future studies
will determine the critical window of repair and identify
the mechanism that serves to enhance neuroplasticity and
functional recovery.
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